HYLORIS PHARMACEUTICALS SA (HYL.BR) Fundamental Analysis & Valuation

EBR:HYL • BE0974363955

6.32 EUR
-0.32 (-4.82%)
Last: Mar 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This HYL.BR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

HYL gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 50 industry peers in the Pharmaceuticals industry. While HYL seems to be doing ok healthwise, there are quite some concerns on its profitability. HYL shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

1

1. HYL.BR Profitability Analysis

1.1 Basic Checks

  • In the past year HYL has reported negative net income.
  • In the past year HYL has reported a negative cash flow from operations.
  • HYL had negative earnings in each of the past 5 years.
  • In the past 5 years HYL always reported negative operating cash flow.
HYL.BR Yearly Net Income VS EBIT VS OCF VS FCFHYL.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -17.31%, HYL is doing worse than 77.55% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -22.20%, HYL is doing worse than 75.51% of the companies in the same industry.
Industry RankSector Rank
ROA -17.31%
ROE -22.2%
ROIC N/A
ROA(3y)-22.4%
ROA(5y)-19.16%
ROE(3y)-27.06%
ROE(5y)-23.47%
ROIC(3y)N/A
ROIC(5y)N/A
HYL.BR Yearly ROA, ROE, ROICHYL.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

  • The Gross Margin of HYL (96.63%) is better than 97.96% of its industry peers.
  • HYL's Gross Margin has improved in the last couple of years.
  • HYL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.27%
GM growth 5Y28.78%
HYL.BR Yearly Profit, Operating, Gross MarginsHYL.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. HYL.BR Health Analysis

2.1 Basic Checks

  • HYL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, HYL has about the same amount of shares outstanding.
  • Compared to 5 years ago, HYL has more shares outstanding
  • The debt/assets ratio for HYL is higher compared to a year ago.
HYL.BR Yearly Shares OutstandingHYL.BR Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
HYL.BR Yearly Total Debt VS Total AssetsHYL.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • HYL has an Altman-Z score of 10.60. This indicates that HYL is financially healthy and has little risk of bankruptcy at the moment.
  • HYL's Altman-Z score of 10.60 is amongst the best of the industry. HYL outperforms 97.96% of its industry peers.
  • HYL has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
  • With an excellent Debt to Equity ratio value of 0.06, HYL belongs to the best of the industry, outperforming 87.76% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 10.6
ROIC/WACCN/A
WACC7.95%
HYL.BR Yearly LT Debt VS Equity VS FCFHYL.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

  • HYL has a Current Ratio of 3.82. This indicates that HYL is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 3.82, HYL belongs to the best of the industry, outperforming 95.92% of the companies in the same industry.
  • HYL has a Quick Ratio of 3.80. This indicates that HYL is financially healthy and has no problem in meeting its short term obligations.
  • HYL's Quick ratio of 3.80 is amongst the best of the industry. HYL outperforms 95.92% of its industry peers.
Industry RankSector Rank
Current Ratio 3.82
Quick Ratio 3.8
HYL.BR Yearly Current Assets VS Current LiabilitesHYL.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. HYL.BR Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 46.05% over the past year.
  • HYL shows a strong growth in Revenue. In the last year, the Revenue has grown by 44.15%.
  • HYL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 147.54% yearly.
EPS 1Y (TTM)46.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.01%
Revenue 1Y (TTM)44.15%
Revenue growth 3Y39.79%
Revenue growth 5Y147.54%
Sales Q2Q%-27.33%

3.2 Future

  • Based on estimates for the next years, HYL will show a very strong growth in Earnings Per Share. The EPS will grow by 44.80% on average per year.
  • The Revenue is expected to grow by 102.83% on average over the next years. This is a very strong growth
EPS Next Y38.32%
EPS Next 2Y31.09%
EPS Next 3Y44.8%
EPS Next 5YN/A
Revenue Next Year77.8%
Revenue Next 2Y99.59%
Revenue Next 3Y102.83%
Revenue Next 5YN/A

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
HYL.BR Yearly Revenue VS EstimatesHYL.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
HYL.BR Yearly EPS VS EstimatesHYL.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. HYL.BR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for HYL. In the last year negative earnings were reported.
  • Also next year HYL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HYL.BR Price Earnings VS Forward Price EarningsHYL.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HYL.BR Per share dataHYL.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • HYL's earnings are expected to grow with 44.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.09%
EPS Next 3Y44.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HYL.BR Dividend Analysis

5.1 Amount

  • No dividends for HYL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HYL.BR Fundamentals: All Metrics, Ratios and Statistics

HYLORIS PHARMACEUTICALS SA

EBR:HYL (3/6/2026, 7:00:00 PM)

6.32

-0.32 (-4.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-25
Earnings (Next)03-26
Inst Owners0.02%
Inst Owner ChangeN/A
Ins Owners56.74%
Ins Owner ChangeN/A
Market Cap176.96M
Revenue(TTM)7.32M
Net Income(TTM)-6.41M
Analysts80
Price Target13.84 (118.99%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)59.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 24.16
P/FCF N/A
P/OCF N/A
P/B 6.13
P/tB 7.1
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0.26
BVpS1.03
TBVpS0.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17.31%
ROE -22.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.63%
FCFM N/A
ROA(3y)-22.4%
ROA(5y)-19.16%
ROE(3y)-27.06%
ROE(5y)-23.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.27%
GM growth 5Y28.78%
F-Score3
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 69.05%
Cap/Sales 6.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.82
Quick Ratio 3.8
Altman-Z 10.6
F-Score3
WACC7.95%
ROIC/WACCN/A
Cap/Depr(3y)212.59%
Cap/Depr(5y)303.89%
Cap/Sales(3y)40.52%
Cap/Sales(5y)102.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.01%
EPS Next Y38.32%
EPS Next 2Y31.09%
EPS Next 3Y44.8%
EPS Next 5YN/A
Revenue 1Y (TTM)44.15%
Revenue growth 3Y39.79%
Revenue growth 5Y147.54%
Sales Q2Q%-27.33%
Revenue Next Year77.8%
Revenue Next 2Y99.59%
Revenue Next 3Y102.83%
Revenue Next 5YN/A
EBIT growth 1Y55.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year81.14%
EBIT Next 3Y72.96%
EBIT Next 5YN/A
FCF growth 1Y36.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.01%
OCF growth 3YN/A
OCF growth 5YN/A

HYLORIS PHARMACEUTICALS SA / HYL.BR FAQ

What is the fundamental rating for HYL stock?

ChartMill assigns a fundamental rating of 4 / 10 to HYL.BR.


What is the valuation status of HYLORIS PHARMACEUTICALS SA (HYL.BR) stock?

ChartMill assigns a valuation rating of 1 / 10 to HYLORIS PHARMACEUTICALS SA (HYL.BR). This can be considered as Overvalued.


Can you provide the profitability details for HYLORIS PHARMACEUTICALS SA?

HYLORIS PHARMACEUTICALS SA (HYL.BR) has a profitability rating of 1 / 10.


What is the earnings growth outlook for HYLORIS PHARMACEUTICALS SA?

The Earnings per Share (EPS) of HYLORIS PHARMACEUTICALS SA (HYL.BR) is expected to grow by 38.32% in the next year.